BioSpace News Archive

Faron Pharmaceuticals Ltd announces that results from the melanoma cohort in the ongoing phase I/II MATINS trial, will be presented at the 18th Congress of the European Association of Dermato-Oncology, being held in Seville, Spain, April 21 to April 23, 2022.

Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on April 20, 2022 to close the consolidated financial statements for the year ending December 31, 2021, announces its full-year results for 2021 and business indicators for the first quarter of 2022.

GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, added a record five pharmacogenetic companies as customers in the first quarter of 2022.

Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

C2N Diagnostics, a leader in advanced brain health diagnostics, announced today that the Journal of the American Medical Association Network Open, a peer-reviewed medical journal from the American Medical Association, has published the combined results from two independent studies for the PrecivityAD™ blood test, which aids healthcare providers in diagnosing Alzheimer’s disease.

Pfizer Canada ULC is recalling all lots of the prescription drug Accupril in 10 mg, 20 mg and 40 mg strengths due to the presence of a nitrosamine impurity above the acceptable level.

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added saliva to the list of validated samples for their PlexPCR® SARS-CoV-2 qPCR diagnostic for COVID-19 sales across Europe#.

Bridge to Life, Ltd. (“Bridge to Life” or the “Company”), a leading global supplier of organ preservation solutions and organ perfusion technologies, announced breakthrough device designation authorization by the U.S. Food and Drug Administration (FDA) for its LifeCradle® Heart Preservation Transport System.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of new and updated websites for its two products, Ameluz® and Xepi®.

Curebase, a company committed to democratizing access to clinical studies, today announced the initiation of the pilot phase of COMPANION, the first clinical investigation of a new digital therapeutic (DTx) for patients with IPF, a rare lung disease.